US2018344705A1PendingUtilityA1

Method for treating chronic inflammatory diseases

54
Assignee: LIGAND PHARM INCPriority: Mar 31, 2009Filed: Mar 28, 2018Published: Dec 6, 2018
Est. expiryMar 31, 2029(~2.7 yrs left)· nominal 20-yr term from priority
Inventors:Jinkun ZhangZofia E. DziewanowskaRene BelderIan HendersonJoseph B. BogardusZhaoying Zhang
A61P 35/00A61P 43/00A61P 9/06A61P 9/10A61P 37/02A61P 9/08A61P 9/00A61P 9/04A61P 3/10A61P 9/12A61P 7/00A61P 25/00A61P 25/06A61P 25/08A61P 27/02A61P 29/00A61P 25/14A61P 17/00A61P 11/00A61P 19/08A61P 13/02A61P 17/06A61P 1/12A61P 13/10A61P 1/04A61P 13/00A61P 13/08A61P 19/02A61P 13/12A61P 1/16A61P 11/06A61P 1/18A61K 9/2059A61K 9/2031A61K 9/2054A61K 31/422A61K 9/2018A61K 9/2013C07D 413/12
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods of administering and pharmaceutical compositions of a biphenyl sulfonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.

Claims

exact text as granted — not AI-modified
1 .- 35 . (canceled) 
     
     
         36 . A method of treating a chronic inflammatory disease, comprising administering to a subject in need thereof an effective amount of a compound of Formula I: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof. 
       
     
     
         37 . The method according to  claim 36 , wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 100 mg/day, 200 mg/day, 400 mg/day, 800 mg/day or 1000 mg/day. 
     
     
         38 . The method according to  claim 36 , wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 100 mg/day. 
     
     
         39 . The method according to  claim 36 , wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 200 mg/day. 
     
     
         40 . The method according to  claim 36 , wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 400 mg/day. 
     
     
         41 . The method according to  claim 36 , wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 800 mg/day. 
     
     
         42 . The method according to  claim 36 , wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 1000 mg/day. 
     
     
         43 . The method according to  claim 36 , wherein the chronic inflammatory disease is arthritis. 
     
     
         44 . The method according to  claim 36 , wherein the chronic inflammatory disease is rheumatoid arthritis. 
     
     
         45 . The method according to  claim 36 , wherein the chronic inflammatory disease is osteoarthritis. 
     
     
         46 . The method according to  claim 36 , wherein the chronic inflammatory disease is sarcoidosis. 
     
     
         47 . The method according to  claim 36 , wherein the chronic inflammatory disease is eczematous dermatitis.

Join the waitlist — get patent alerts

Track US2018344705A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.